News

Diastolic perfusion pressure emerges as the strongest predictor of myocardial strain in a recent study.

ECG-synchronized Doppler holography provides repeatable measurements of the retinal blood flow

The poster looked into the LLM's potential for biases in gender and race when it came to its knowledge of retinitis pigmentosa.

New pathways are reshaping the management of retinal disease.

Srinivas Sadda, MD, FARVO, immediate past president of ARVO, discusses the impact the organization has had on his career and how he wants to help the next generation.

Kaden Bunch, a fourth-year medical student from the Warren Alpert Medical School of Brown University, talked about his poster on large language models and the effectiveness of diagnosing red eye diseases.

At this year's ARVO meeting in Denver, Colorado, Giulia Corradetti spoke on how baseline OCT biomarkers can predict anatomic response in neovascular age-related macular degeneration when treated with faricimab.

In addition to ChatGPT for Clinicians, OpenAI introduced ChatGPT for Healthcare earlier this year.

Researchers noted growing evidence supporting an additional role for B vitamins.

New SOL-X extension follows AXPAXLI implant in wet AMD for 3 years, probing 24-week dosing durability, safety and vision protection.

Professor Alió reflects on a new comprehensive volume dedicated to aging in ophthalmology

According to the company, the NDA submission is supported by data from the phase 3 DRAGON trial.

SOL-1 data show AXPAXLI extends wet AMD control, delaying fluid rebound and reducing rescue injections while sustaining vision through 52 weeks.

Melding ophthalmology and neurology

Temporal optical coherence tomography modelling may improve longitudinal disease tracking.

New expert‑led series explores how ophthalmic innovations move from early development to market‑ready therapies through cross‑functional collaboration.

Phase 3 data show brolucizumab outperforms laser for PDR vision preservation, with fewer adverse events—while monitoring inflammation risk.

From role models to open doors, Christina Y. Weng, MD, MBA, FASRS, shares insights on career development, women in ophthalmology, evolving training models, and her work as protocol chair for the DRCR Retina Network’s Protocol AO study.

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

The dual-function phaco-vitrectomy platform is cleared for European commercialization, with launch targeted for Q3 2026.

A tissue-sparing technique using a triple-layer decellularized basement membrane is associated with shorter OR time, rapid recovery, and no reported recurrences in a retrospective series.

The company noted it expects topline results in June 2026.

Understanding thyroid eye disease and its often-missed diagnosis.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

Quesada discusses a robotic femtosecond laser platform for LASIK, focusing on flap accuracy, stromal bed precision, and the role of integrated OCT imaging.